FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Holly Gallion

Research Profile

Disorders

Concepts & Ideas

Procedures

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Thomas Krivak; Kathleen M Darcy; Chunqiao Tian; Michael Bookman; Holly H Gallion; Christine B Ambrosone; Julie A DeLoia
Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.
Warner K Huh; Michael Cibull; Holly H Gallion; Christine M Gan; Scott Richard; David E Cohn
Consistency of in vitro chemoresponse assay results and population clinical response rates among women with endometrial carcinoma.
Kathleen N Moore; Chunqiao Tian; D Scott McMeekin; J Tate Thigpen; Marcus E Randall; Holly H Gallion
Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Holly Gallion (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Thomas Krivak; Kathleen M Darcy; Chunqiao Tian; Michael Bookman; Holly H Gallion; Christine B Ambrosone; Julie A DeLoia
Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.
Gynecologic oncology 2011;122(1):121-6.
2011: Warner K Huh; Michael Cibull; Holly H Gallion; Christine M Gan; Scott Richard; David E Cohn
Consistency of in vitro chemoresponse assay results and population clinical response rates among women with endometrial carcinoma.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2011;21(3):494-9.
2010: Kathleen N Moore; Chunqiao Tian; D Scott McMeekin; J Tate Thigpen; Marcus E Randall; Holly H Gallion
Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis.
Cancer 2010;116(23):5407-14.
2010: John H Farley; Chunqiao Tian; G Scott Rose; Carol L Brown; Michael J Birrer; John Risinger; J Tate Thigpen; Gini F Fleming; Holly H Gallion; G Larry Maxwell
Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study.
Cancer 2010;116(2):355-61.
2009: Ronald D Alvarez; Robert Mannel; Agustin A García; Holly H Gallion; Joseph Lucci; Larry C Kilgore; T Michael Numnum; Sharon Xiaohan Zou; Mauro Orlando; Datchen F Tai
Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian cancer patients: results of a three-arm Phase I study.
Gynecologic oncology 2009;115(3):389-95.
2008: Thomas Krivak; Kathleen M Darcy; Chunqiao Tian; Deborah K Armstrong; Bora E Baysal; Holly H Gallion; Christine B Ambrosone; Julie A DeLoia
Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(21):3598-606.
2008: Zhibao Mi; Frankie A Holmes; Beth Hellerstedt; John Pippen; Rufus Collea; Amanda Backner; Jason E Bush; Holly H Gallion; Alan Wells; Joyce A O'Shaughnessy
Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients.
Anticancer research 2008;28(3B):1733-40.
2008: Julie A DeLoia; William C Zamboni; Jacqueline M Jones; Sandra Strychor; Joseph L Kelley; Holly H Gallion
Expression and activity of taxane-metabolizing enzymes in ovarian tumors.
Gynecologic oncology 2008;108(2):355-60.
2007: Allison E Axtell; Joseph L Kelley; Amanda Fader; Dilip Gupta; Benjamin Schwartz; John T Comerci; Yan Lin; Samuel Weiand; Holly H Gallion; Amal Kanbour-Shakir
Percent surface area involvement is a predictor of lymph node metastasis in endometrial cancer.
Gynecologic oncology 2007;107(3):482-6.
2007: D Scott McMeekin; Virginia L Filiaci; J Tate Thigpen; Holly H Gallion; Gini F Fleming; William H Rodgers
The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
Gynecologic oncology 2007;106(1):16-22.
2007: Melissa M Thrall; Julie A DeLoia; Holly H Gallion; Norbert Avril
Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Gynecologic oncology 2007;105(1):17-22.
2007: Susan C Modesitt; Chunqiao Tian; Richard J Kryscio; J Tate Thigpen; Marcus E Randall; Holly H Gallion; Gini F Fleming
Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study.
Gynecologic oncology 2007;105(1):59-65.
2006: G Larry Maxwell; Chunqiao Tian; John Risinger; Carol L Brown; G Scott Rose; J Tate Thigpen; Gini F Fleming; Holly H Gallion; Wendy Brewster
Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study.
Cancer 2006;107(9):2197-205.
2006: M Thrall; Holly H Gallion; R Kryscio; Malathy Kapali; Deborah K Armstrong; Julie A DeLoia
BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16 Suppl 1():166-71.
2006: Holly H Gallion; W A Christopherson; R L Coleman; L DeMars; T Herzog; S Hosford; H Schellhas; A Wells; B-U Sevin
Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16(1):194-201.
2005: Cathy Wilcox; Bora E Baysal; Holly H Gallion; Mary A Strange; Julie A DeLoia
High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.
Cancer genetics and cytogenetics 2005;159(2):114-22.
2005: Gregory Sutton; James Kauderer; Linda F Carson; Samuel S Lentz; Charles W Whitney; Holly H Gallion
Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study.
Gynecologic oncology 2005;96(3):630-4.
2005: Lih-Ching Hsu; Malathy Kapali; Julie A DeLoia; Holly H Gallion
Centrosome abnormalities in ovarian cancer.
International journal of cancer. Journal international du cancer 2005;113(5):746-51.
2004: Bora E Baysal; Julie A DeLoia; Joan E Willett-Brozick; Marc T Goodman; Mark F Brady; Francesmary Modugno; Henry T Lynch; Yvette P Conley; Patrice Watson; Holly H Gallion
Analysis of CHEK2 gene for ovarian cancer susceptibility.
Gynecologic oncology 2004;95(1):62-9.
2004: Alan N Gordon; Birgit C Schultes; Holly H Gallion; Robert Edwards; Theresa L Whiteside; Jennifer M Cermak; Christopher F Nicodemus
CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients.
Gynecologic oncology 2004;94(2):340-51.
2004: Gini F Fleming; Virginia L Filiaci; R C Bentley; T Herzog; J Sorosky; L Vaccarello; Holly H Gallion
Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(8):1173-8.
2004: Anita S Y Sit; Joseph L Kelley; Holly H Gallion; Alan J Kunschner; Robert P Edwards
Paclitaxel and carboplatin for recurrent or persistent cancer of the cervix.
Cancer investigation 2004;22(3):368-73.
2003: Holly H Gallion; Virginia L Brunetto; Michael Cibull; Samuel S Lentz; Gary Reid; John Soper; Robert A Burger; Willie Andersen
Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(20):3808-13.
2003: Dwight E Heron; Kristina Gerszten; Raj N Selvaraj; Gwendolyn C King; Deborah Sonnik; Holly H Gallion; John T Comerci; Robert P Edwards; Andrew Wu; Regiane S Andrade; Shalom Kalnicki
Conventional 3D conformal versus intensity-modulated radiotherapy for the adjuvant treatment of gynecologic malignancies: a comparative dosimetric study of dose-volume histograms small star, filled.
Gynecologic oncology 2003;91(1):39-45.
2002: Mark Reedy; Holly H Gallion; Jeffrey M Fowler; Richard J Kryscio; Simon A Smith
Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology group study.
Gynecologic oncology 2002;85(2):255-9.
2001: Simon A Smith; WE Richards; K Caito; Parviz Hanjani; Maurie Markman; Koen DeGeest; Holly H Gallion
BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study.
Gynecologic oncology 2001;83(3):586-92.
2001: Mark Reedy; T Hang; Holly H Gallion; S Arnold; Simon A Smith
Antisense inhibition of BRCA1 expression and molecular analysis of hereditary tumors indicate that functional inactivation of the p53 DNA damage response pathway is required for BRCA-associated tumorigenesis.
Gynecologic oncology 2001;81(3):441-6.
2001: M Markman; David Spriggs; R A Burger; L F Carson; Samuel S Lentz; Holly H Gallion
Phase I trial of ifosfamide and 24-h infusional paclitaxel in pelvic malignancies: a Gynecologic Oncology Group study.
Gynecologic oncology 2001;80(3):359-63.
2001: Edward Pavlik; C Liu; Paul D DePriest; Holly H Gallion; Frederick R Ueland; Richard J Kryscio; John R van Nagell
Relating ovarian size to age, menopausal status, and use of hormones.
Gynecologic oncology 2001;80(2):333-4.
2000: Edward Pavlik; Paul D DePriest; Holly H Gallion; Frederick R Ueland; Mark Reedy; Richard J Kryscio; John R van Nagell
Ovarian volume related to age.
Gynecologic oncology 2000;77(3):410-2.
2000: John R van Nagell; Paul D DePriest; Mark Reedy; Holly H Gallion; Frederick R Ueland; Edward Pavlik; Richard J Kryscio
The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer.
Gynecologic oncology 2000;77(3):350-6.
1999: WE Richards; Holly H Gallion; J P Schmittschmitt; D V Holladay; Simon A Smith
BRCA1-related and sporadic ovarian cancer in the same family: implications for genetic testing.
Gynecologic oncology 1999;75(3):468-72.
1998: C L Bailey; Frederick R Ueland; G L Land; Paul D DePriest; Holly H Gallion; Richard J Kryscio; John R van Nagell
The malignant potential of small cystic ovarian tumors in women over 50 years of age.
Gynecologic oncology 1998;69(1):3-7.
1998: Diane D Davey; S Zaleski; M Sattich; Holly H Gallion
Prognostic significance of DNA cytometry of postirradiation cervicovaginal smears.
Cancer 1998;84(1):11-6.
1997: Paul D DePriest; Holly H Gallion; Edward Pavlik; Richard J Kryscio; John R van Nagell
Transvaginal sonography as a screening method for the detection of early ovarian cancer.
Gynecologic oncology 1997;65(3):408-14.
1996: S L Buckley; D M Tritz; Linda Van Le; R Higgins; BU Sevin; Frederick R Ueland; Paul D DePriest; Holly H Gallion; C L Bailey; Richard J Kryscio; Wesley C Fowler; Hervy E Averette; John R van Nagell
Lymph node metastases and prognosis in patients with stage IA2 cervical cancer.
Gynecologic oncology 1996;63(1):4-9.
1996: Larry Puls; T Duniho; James Hunter; Richard J Kryscio; D Blackhurst; Holly H Gallion
The prognostic implication of ascites in advanced-stage ovarian cancer.
Gynecologic oncology 1996;61(1):109-12.
1996: Holly H Gallion; A Guarino; Paul D DePriest; John R van Nagell; L Vaccarello; J S Berek; Maura Pieretti
Evidence for a unifocal origin in familial ovarian cancer.
American journal of obstetrics and gynecology 1996;174(4):1102-6; discussion 1106-8.
1995: Maura Pieretti; C Cavalieri; P S Conway; Holly H Gallion; D E Powell; Mitchell S Turker
Genetic alterations distinguish different types of ovarian tumors.
International journal of cancer. Journal international du cancer 1995;64(6):434-40.
1995: John R van Nagell; Holly H Gallion; Edward Pavlik; Paul D DePriest
Ovarian cancer screening.
Cancer 1995;76(10 Suppl):2086-91.
1995: Holly H Gallion; Maura Pieretti; Paul D DePriest; John R van Nagell
The molecular basis of ovarian cancer.
Cancer 1995;76(10 Suppl):1992-7.
1995: D L Shenson; Holly H Gallion; D E Powell; Maura Pieretti
Loss of heterozygosity and genomic instability in synchronous endometrioid tumors of the ovary and endometrium.
Cancer 1995;76(4):650-7.
1995: Maura Pieretti; D E Powell; Holly H Gallion; P S Conway; E A Case; Mitchell S Turker
Hypermethylation at a chromosome 17 "hot spot" is a common event in ovarian cancer.
Human pathology 1995;26(4):398-401.
1995: Maura Pieretti; D E Powell; Holly H Gallion; E A Case; P S Conway; Mitchell S Turker
Genetic alterations on chromosome 17 distinguish different types of epithelial ovarian tumors.
Human pathology 1995;26(4):393-7.
1994: James Hunter; D E Tritz; M G Howell; Paul D DePriest; Holly H Gallion; S J Andrews; S B Buckley; Richard J Kryscio; John R van Nagell
The prognostic and therapeutic implications of cytologic atypia in patients with endometrial hyperplasia.
Gynecologic oncology 1994;55(1):66-71.
1994: S J Andrews; B T Williams; Paul D DePriest; Holly H Gallion; James Hunter; S L Buckley; Richard J Kryscio; John R van Nagell
Therapeutic implications of lymph nodal spread in lateral T1 and T2 squamous cell carcinoma of the vulva.
Gynecologic oncology 1994;55(1):41-6.
1994: Holly H Gallion; S A Smith
Hereditary ovarian carcinoma.
Seminars in surgical oncology 1994;10(4):249-54.
1994: Y Maruyama; M G Bowen; John R van Nagell; Holly H Gallion; Paul D DePriest; JG Wierzbicki
A feasibility study of 252Cf neutron brachytherapy, cisplatin + 5-FU chemo-adjuvant and accelerated hyperfractionated radiotherapy for advanced cervical cancer.
International journal of radiation oncology, biology, physics 1994;29(3):529-34.
1993: D E Kenady; Edward Pavlik; K Nelson; John R van Nagell; Holly H Gallion; Paul D DePriest; U Y Ryo; R J Baranczuk
Images of estrogen-receptor-positive breast tumors produced by estradiol labeled with iodine I 123 at 16 alpha.
Archives of surgery (Chicago, Ill. : 1960) 1993;128(12):1373-81.
1993: Paul D DePriest; John R van Nagell; Holly H Gallion; D Shenson; James Hunter; S J Andrews; D E Powell; Edward Pavlik
Ovarian cancer screening in asymptomatic postmenopausal women.
Gynecologic oncology 1993;51(2):205-9.
1993: Paul D DePriest; D Shenson; A Fried; James Hunter; S J Andrews; Holly H Gallion; Edward Pavlik; Richard J Kryscio; John R van Nagell
A morphology index based on sonographic findings in ovarian cancer.
Gynecologic oncology 1993;51(1):7-11.
1993: Holly H Gallion; R C Bast
National Cancer Institute Conference on Investigational Strategies for Detection and Intervention in Early Ovarian Cancer.
Cancer research 1993;53(16):3839-42.
1993: Y Maruyama; John R van Nagell; J Yoneda; Holly H Gallion; Paul D DePriest; J M Feola; JG Wierzbicki
Schedule in Cf-252 neutron brachytherapy: complications after delayed implant therapy for cervical cancer in a phase II trial.
American journal of clinical oncology 1993;16(2):168-74.
1993: Larry Puls; D D Davey; Paul D DePriest; Holly H Gallion; John R van Nagell; James Hunter; Edward Pavlik
Immunohistochemical staining for CA-125 in fallopian tube carcinomas.
Gynecologic oncology 1993;48(3):360-3.
1993: John R van Nagell; Paul D DePriest; Holly H Gallion; Edward Pavlik
Ovarian cancer screening.
Cancer 1993;71(4 Suppl):1523-8.
1992: Holly H Gallion; D E Powell; J K Morrow; Maura Pieretti; E Case; Mitchell S Turker; Paul D DePriest; James Hunter; John R van Nagell
Molecular genetic changes in human epithelial ovarian malignancies.
Gynecologic oncology 1992;47(2):137-42.
1992: Paul D DePriest; E R Banks; D E Powell; John R van Nagell; Holly H Gallion; Larry Puls; James Hunter; Richard J Kryscio; M B Royalty
Endometrioid carcinoma of the ovary and endometriosis: the association in postmenopausal women.
Gynecologic oncology 1992;47(1):71-5.
1992: Larry Puls; D E Powell; Paul D DePriest; Holly H Gallion; James Hunter; Richard J Kryscio; John R van Nagell
Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma.
Gynecologic oncology 1992;47(1):53-7.
1992: Diane D Davey; Holly H Gallion; C Darrell Jennings
DNA cytometry in postirradiation cervical-vaginal smears.
Human pathology 1992;23(9):1027-31.
1992: Edward Pavlik; K Nelson; S Srinivasan; D E Powell; D E Kenady; Paul D DePriest; Holly H Gallion; John R van Nagell
Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity.
Cancer research 1992;52(15):4106-12.
1992: Holly H Gallion; P Y Liu; D E Alberts; R V O'Toole; J O'Sullivan; G Mills; Harriet O Smith; H E Hynes
Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: a Southwest Oncology Group study.
Gynecologic oncology 1992;46(2):230-2.
1992: Holly H Gallion; James Hunter; John R van Nagell; Hervy E Averette; JM Cain; L J Copeland; Robert V Higgins; Nader Husseinzadeh; W A Nahhas; Edward E Partridge
The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer.
Gynecologic oncology 1992;46(1):29-32.
1992: Y Maruyama; John R van Nagell; D Powell; J Yoneda; E Donaldson; Holly H Gallion; Richard J Kryscio
Predictive value of specimen histology after preoperative radiotherapy in the treatment of bulky/barrel carcinoma of the cervix.
American journal of clinical oncology 1992;15(2):150-6.
1991: Y Maruyama; E Donaldson; John R van Nagell; J Yoneda; Holly H Gallion; D Powell; Richard J Kryscio
Specimen findings and survival after preoperative 252Cf neutron brachytherapy for stage II cervical carcinoma.
Gynecologic oncology 1991;43(3):252-9.
1991: Robert V Higgins; John R van Nagell; E J Horn; S L Roberts; E S Donaldson; Holly H Gallion; Paul D DePriest; D E Powell; Richard J Kryscio
Preoperative radiation therapy followed by extrafascial hysterectomy in patients with stage II endometrial carcinoma.
Cancer 1991;68(6):1261-4.
1991: Y Maruyama; John R van Nagell; J Yoneda; E S Donaldson; Holly H Gallion; D Powell; Richard J Kryscio
A review of californium-252 neutron brachytherapy for cervical cancer.
Cancer 1991;68(6):1189-97.
1991: John R van Nagell; Paul D DePriest; Larry Puls; E S Donaldson; Holly H Gallion; Edward Pavlik; D E Powell; Richard J Kryscio
Ovarian cancer screening in asymptomatic postmenopausal women by transvaginal sonography.
Cancer 1991;68(3):458-62.
1990: Edward Pavlik; K Nelson; Holly H Gallion; John R van Nagell; E S Donaldson; W J Shih; J A Spicer; D F Preston; R J Baranczuk; D E Kenady
Characterization of high specific activity [16 alpha-123I]Iodo-17 beta-estradiol as an estrogen receptor-specific radioligand capable of imaging estrogen receptor-positive tumors.
Cancer research 1990;50(24):7799-805.
1990: Holly H Gallion; D E Powell; L W Smith; J K Morrow; A W Martin; John R van Nagell; E S Donaldson
Chromosome abnormalities in human epithelial ovarian malignancies.
Gynecologic oncology 1990;38(3):473-7.
1990: Y Maruyama; John R van Nagell; J Yoneda; E S Donaldson; Holly H Gallion; R Higgins; Richard J Kryscio
Cure of cervical cancer using 252Cf neutron brachytherapy.
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 1990;166(5):317-21.
1990: John R van Nagell; Robert V Higgins; E S Donaldson; Holly H Gallion; D E Powell; Edward Pavlik; C H Woods; E A Thompson
Transvaginal sonography as a screening method for ovarian cancer. A report of the first 1000 cases screened.
Cancer 1990;65(3):573-7.
1990: Robert V Higgins; John R van Nagell; E S Donaldson; Holly H Gallion; Edward Pavlik; Richard J Kryscio
The efficacy of laser therapy in the treatment of cervical intraepithelial neoplasia.
Gynecologic oncology 1990;36(1):79-81.
1989: K Nelson; J Baranowska-Kortylewicz; John R van Nagell; Holly H Gallion; E S Donaldson; D E Kenady; W P McRoberts; Edward Pavlik
Intermolecular engagement of estrogen receptors indicated by the formation of a high molecular weight complex during activation.
Biochemistry 1989;28(25):9741-9.
1989: Robert V Higgins; John R van Nagell; E S Donaldson; Holly H Gallion; Edward Pavlik; B Endicott; C H Woods
Transvaginal sonography as a screening method for ovarian cancer.
Gynecologic oncology 1989;34(3):402-6.
1989: Holly H Gallion; John R van Nagell; E S Donaldson; Robert V Higgins
Successful salvage therapy of resistant gestational trophoblastic disease with etoposide, methotrexate, dactinomycin, vincristine, and cyclophosphamide.
Gynecologic oncology 1989;34(1):98-100.
1989: Holly H Gallion; John R van Nagell; D F Powell; E S Donaldson; Robert V Higgins; Richard J Kryscio; Edward Pavlik; K Nelson
Stage I serous papillary carcinoma of the endometrium.
Cancer 1989;63(11):2224-8.
1989: Holly H Gallion; John R van Nagell; E S Donaldson; Robert V Higgins; D E Powell; Richard J Kryscio
Adjuvant oral alkylating chemotherapy in patients with stage I epithelial ovarian cancer.
Cancer 1989;63(6):1070-3.
1989: Y Maruyama; John R van Nagell; J Yoneda; E Donaldson; Holly H Gallion; R Higgins; D Powell; Richard J Kryscio; B Berner
Dose-response and failure pattern for bulky or barrel-shaped stage IB cervical cancer treated by combined photon irradiation and extrafascial hysterectomy.
Cancer 1989;63(1):70-6.
1988: John R van Nagell; D E Powell; Holly H Gallion; D G Elliott; E S Donaldson; A E Carpenter; Robert V Higgins; Richard J Kryscio; Edward Pavlik
Small cell carcinoma of the uterine cervix.
Cancer 1988;62(8):1586-93.
1988: K C Rowley; Holly H Gallion; E S Donaldson; John R van Nagell; Robert V Higgins; D E Powell; Richard J Kryscio; Edward Pavlik
Prognostic factors in early vulvar cancer.
Gynecologic oncology 1988;31(1):43-9.
1988: Y Maruyama; John R van Nagell; J Yoneda; E Donaldson; Holly H Gallion; P Patel; Richard J Kryscio
Feasibility study of Californium-252 for the therapy of stage IV cervical cancer.
Cancer 1988;61(12):2448-52.
1988: Y Maruyama; John R van Nagell; J Yoneda; E Donaldson; Holly H Gallion; R Higgins; D Powell; C Turner; Richard J Kryscio
Efficacy of brachytherapy with californium-252 neutrons versus cesium-137 photons for eradication of bulky localized cervical cancer: single-institution study.
Journal of the National Cancer Institute 1988;80(7):501-6.
1988: Holly H Gallion; John R van Nagell; E S Donaldson; D E Powell
Ovarian dysgerminoma: report of seven cases and review of the literature.
American journal of obstetrics and gynecology 1988;158(3 Pt 1):591-5.
1988: Daniel P Wermeling; T S Foster; Elizabeth Farrington; W O Witt; Holly H Gallion; E Donaldson; John R van Nagell; W R Outman; D P McPherson
Patient-controlled analgesia using butorphanol for postoperative pain relief: an open-label study.
Acute care 1988;12 Suppl 1():31-9.
1987: Y Maruyama; John R van Nagell; J M Feola; J L Beach; J Yoneda; E Donaldson; Holly H Gallion; K Rowley; D Powell
Specimen histology after one or two preoperative CF-252 implants for bulky stage IB cervical cancer.
International journal of radiation oncology, biology, physics 1987;13(10):1473-8.
1987: Holly H Gallion; Daniel P Wermeling; T S Foster; John R van Nagell; E S Donaldson
Patient-controlled analgesia in gynecologic oncology.
Gynecologic oncology 1987;27(3):247-53.
1987: Holly H Gallion; John R van Nagell; E S Donaldson; M B Hanson; Richard J Kryscio
Prognostic implications of large volume residual disease in patients with advanced stage epithelial ovarian cancer.
Gynecologic oncology 1987;27(2):220-5.
1987: Holly H Gallion; Y Maruyama; John R van Nagell; E S Donaldson; K C Rowley; J Yoneda; J L Beach; D E Powell; Richard J Kryscio
Treatment of stage IIIB cervical cancer with Californium-252 fast-neutron brachytherapy and external photon therapy.
Cancer 1987;59(10):1709-12.
1987: J Baranowska-Kortylewicz; K Nelson; Edward Pavlik; John R van Nagell; Holly H Gallion; E S Donaldson; D E Kenady
Identification of a very large nuclear estrogen receptor complex.
Endocrinology 1987;120(5):2189-91.
1987: Y Maruyama; J R VanNagell; J Yoneda; E Donaldson; Holly H Gallion; K Rowley; Richard J Kryscio; J L Beach
Phase I-II clinical trial of Californium-252. Treatment of stage IB carcinoma of the cervix.
Cancer 1987;59(8):1500-5.
1987: Edward Pavlik; K Nelson; John R van Nagell; E S Donaldson; M L Walden; Holly H Gallion; D E Kenady
Extensive in situ activation of nuclear estrogen receptors after exposure of murine uteri to [3H]estradiol or [3H]4-hydroxytamoxifen.
Endocrinology 1987;120(4):1608-14.
1986: John R van Nagell; Y Maruyama; E S Donaldson; M B Hanson; Holly H Gallion; J Yoneda; D E Powell; Richard J Kryscio; J L Beach
Phase II clinical trial using californium 252 fast neutron brachytherapy, external pelvic radiation, and extrafascial hysterectomy in the treatment of bulky, barrel-shaped stage IB cervical cancer.
Cancer 1986;57(10):1918-22.
1986: Edward Pavlik; John R van Nagell; K Nelson; Holly H Gallion; E S Donaldson; D E Kenady; J Baranowska-Kortylewicz
Antagonism to estradiol in the mouse: reduced entry of receptors complexed with 4-hydroxytamoxifen into a Mg2+-soluble chromatin fraction.
Endocrinology 1986;118(5):1924-34.
1986: John R van Nagell; M B Hanson; E S Donaldson; Holly H Gallion
Adjuvant vincristine, dactinomycin, and cyclophosphamide therapy in stage I uterine sarcomas. A pilot study.
Cancer 1986;57(8):1451-4.
1985: Edward Pavlik; K Nelson; John R van Nagell; E S Donaldson; M L Walden; M B Hanson; Holly H Gallion; R C Flanigan; D E Kenady
Hydrodynamic characterizations of estrogen receptors complexed with [3H]-4-hydroxytamoxifen: evidence in support of contrasting receptor transitions mediated by different ligands.
Biochemistry 1985;24(27):8101-6.
1985: John R van Nagell; M B Hanson; E S Donaldson; Holly H Gallion
Treatment of cervical intraepithelial neoplasia III by hysterectomy without intervening conization in patients with adequate colposcopy.
Cancer 1985;56(12):2737-9.
1985: Holly H Gallion; John R van Nagell; E S Donaldson; M B Hanson; D E Powell; Y Maruyama; J Yoneda
Combined radiation therapy and extra-fascial hysterectomy in the treatment of stage IB barrel-shaped cervical cancer.
Cancer 1985;56(2):262-5.
1985: M B Hanson; John R van Nagell; D E Powell; E S Donaldson; Holly H Gallion; M Merhige; Edward Pavlik
The prognostic significance of lymph-vascular space invasion in stage I endometrial cancer.
Cancer 1985;55(8):1753-7.
1983: Holly H Gallion; John R van Nagell; E S Donaldson; M B Hanson; D F Powell
Immature teratoma of the ovary.
American journal of obstetrics and gynecology 1983;146(4):361-5.